Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
University of California, San Francisco
National Cancer Institute (NCI)
Mayo Clinic
Alliance for Clinical Trials in Oncology
Jonsson Comprehensive Cancer Center
Swiss Cancer Institute
Mayo Clinic
European Organisation for Research and Treatment of Cancer - EORTC
Children's Oncology Group
First Affiliated Hospital of Zhejiang University
AIDS Malignancy Consortium
St. Jude Children's Research Hospital
University Health Network, Toronto
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Emory University
Sun Yat-sen University
Children's Oncology Group
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Tokyo Medical and Dental University
Tianjin Medical University Cancer Institute and Hospital
University of Michigan Rogel Cancer Center
SWOG Cancer Research Network
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
University Hospital, Bonn
Mayo Clinic
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shanghai Zhongshan Hospital
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Eye & ENT Hospital of Fudan University
Northwestern University
Swiss Cancer Institute
Pusan National University Hospital
University Hospital, Lille
Xijing Hospital
Eye & ENT Hospital of Fudan University
Philogen S.p.A.
Fondazione Ricerca Traslazionale
Institut Bergonié
Women's Hospital School Of Medicine Zhejiang University
University of Michigan Rogel Cancer Center
Norwegian Department of Health and Social Affairs
University Hospital, Basel, Switzerland
Washington University School of Medicine
M.D. Anderson Cancer Center